Salim Syed
Stock Analyst at Mizuho
(2.33)
# 2,604
Out of 5,124 analysts
77
Total ratings
43.55%
Success rate
0.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $98.77 | +22.51% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $34.01 | +17.61% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.85 | +656.76% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $63.54 | +32.20% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $175.99 | -3.97% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $327.31 | -14.45% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $122.74 | -4.68% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $17.00 | +29.41% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $46.14 | +253.27% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $18.09 | -0.50% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $15.40 | +120.78% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $52.44 | +88.79% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $76.49 | -30.71% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.43 | +1,371.62% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $98.77
Upside: +22.51%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $34.01
Upside: +17.61%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.85
Upside: +656.76%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $63.54
Upside: +32.20%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $175.99
Upside: -3.97%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $327.31
Upside: -14.45%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $122.74
Upside: -4.68%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $17.00
Upside: +29.41%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $46.14
Upside: +253.27%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $18.09
Upside: -0.50%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $15.40
Upside: +120.78%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $52.44
Upside: +88.79%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $76.49
Upside: -30.71%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.43
Upside: +1,371.62%